bioRxivCell Biology
LOXL2-dependent deacetylation of aldolase A induces metabolic reprogramming and tumor progression
J.-W. Jiao, X.-H. Zhan, J.-J. Wang, L.-X. He, Z.-C. Guo, X.-E. Xu, L.-D. Liao, X. Huang, B. Wen, Y.-W. Xu, H. Hu, G. Neufeld, Z.-J. Chang, K. Zhang, L.-Y. Xu, E.-M. Li
Abstract
Lysyl-oxidase like-2 (LOXL2) regulates extracellular matrix remodeling and promotes tumor invasion and metastasis. Altered metabolism is a core hallmark of cancer, however, it remains unclear whether and how LOXL2 contributes to tumor metabolism. Here, we found that LOXL2 and its catalytically inactive L2{Delta}13 splice variant also function as novel deacetylases that trigger metabolic reprogramming during malignant transformation. Integrated transcriptomic and metabolomic analysis revealed that L2{Delta}13-overexpressing transgenic mice displayed perturbed glucose and lipid metabolism, which was associated with increased hepatic fibrosis and enhanced formation of precancerous lesions induced by chemical carcinogens, such as carbon tetrachloride and N-nitrosomethylbenzylamine. Furthermore, both LOXL2 and L2{Delta}13 boosted glucose metabolism of esophageal tumor cells, thereby facilitating tumor cell proliferation in vitro and in vivo. Mechanistically, LOXL2 and L2{Delta}13 interacted physically with several glycolic proteins including aldolase A to enhance their enzymatic activities and mobilization from the actin cytoskeleton. Using SILAC followed by proteomic analysis, we identified LOXL2 as a deacetylase targeting metabolic proteins in esophageal cancer. Importantly, both LOXL2 and L2{Delta}13 directly catalyzed the deacetylation of aldolase A at K13, resulting in enhanced glycolysis which subsequently reprogramed tumor metabolism and promoted tumor progression. High level expression of LOXL2/L2{Delta}13 combined with decreased acetylation of aldolase-K13 predicted poor clinical outcome in patients with esophageal cancer. In summary, we have characterized a novel molecular mechanism that mediates the pro-tumorigenic activity of LOXL2 independently of its classical amine oxidase activity. These findings may enable the future development of therapeutic agents targeting the metabolic machinery via LOXL2 or L2{Delta}13.
- organism: mouse
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lysyl oxidase inhibition drives the transdifferentiation from lung adenocarcinoma to squamous cell carcinoma in mice
Shun Yao, Xiangkun Han, … Ji Hongbin·bioRxiv·Jun 10, 2018
- Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation
A. van Weverwijk, N. Koundouros, … C. Isacke·bioRxiv·Jul 11, 2018
- SLC13A2-transported citrate is a metabolic signal for PKM2 acetylation and degradation to suppress tumor growth
Mengyao Qin, Li Shi, … Jing Xiong·Science AdvancesPeer-reviewed·Apr 8, 2026
- A positive feedback loop between ZEB2 and ACSL4 regulates lipid metabolism to promote breast cancer metastasis
- ALDH2 Knockout Induces Dysregulation of Arginine biosynthesis in SKBR-3 Breast Cancer Cells
Ming Zhao, Blake R. Rushing, … Xiaohe Yang·bioRxiv·Sep 22, 2026
- Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing Aldob/Akt/PP2A protein complex